Combination-level molecular target

The term 'Combination-level molecular target' is not a recognized biological entity, such as a specific protein, enzyme, or receptor. Rather, it is a nomenclature used in pharmacological databases and high-throughput screening studies to categorize therapeutic interventions that act upon multiple molecular targets simultaneously [1, 3]. This classification is often applied to drug combinations or multi-target (promiscuous) drugs where the observed phenotypic effect cannot be attributed to a single molecular interaction but emerges from the collective modulation of a network of targets [4, 5]. In bioinformatics, this term may appear as a placeholder for data aggregated at the level of a drug pair or a multi-protein complex, reflecting the complexity of polypharmacology [2]. Because it represents a conceptual grouping rather than a discrete molecule, it lacks specific biochemical properties, such as a molecular weight or a conserved amino acid sequence. It is primarily used to describe the granularity of experimental data in synergy screens, where results are reported at the 'combination level' rather than for individual agents [1]. Consequently, it does not have a direct role in disease or a specific mechanism of action in the traditional sense, and biotech analysts should treat this as a data-level descriptor for multi-target strategies rather than a druggable protein.

Other names

Multi-targetPolypharmacology targetDrug combination targetMulti-component target

Not applicable (classification term)